Education
About Us
Working with TipRanks
Follow Us
Invivyd (IVVD)
NASDAQ:IVVD
Earnings Data
Report Date
Aug 19, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.02Last Year’s EPS
-0.4Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 15, 2025
|% Change Since: 15.48%
|Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted the successful internalization of the commercial team, pipeline expansion, and strong financial management. However, these positives were offset by a decline in Q1 revenue, regulatory hurdles with EUA expansion, and challenges in healthcare provider adoption. The company expressed confidence in its strategic direction and financial discipline but faces significant challenges in execution and regulatory approval.Company Guidance
During Invivyd’s First Quarter 2025 Earnings Conference Call, the company provided guidance that emphasized the transition to an internal commercial organization, aiming for near-term breakeven with ongoing revenue growth and operating expense management. The management highlighted a strategic focus on broader adoption of PEMGARDA, with promising leading indicators for commercial success. Invivyd secured additional non-dilutive capital contingent on meeting certain conditions and milestones and is expanding its pipeline beyond COVID-19, including discovery programs in new viral targets and diseases such as RSV and measles. The company's strategy includes disciplined financial management, targeting profitability by mid-2025, and leveraging its scientific platform to create shareholder value efficiently. The guidance reflects a commitment to developing high-value medicines rapidly, despite the challenging biotech financing environment.Internalization of Commercial Organization
The company successfully transitioned to an internal commercial team, which is expected to drive broader adoption of PEMGARDA, with promising early indicators for near-term breakeven and continued revenue growth.
Pipeline Expansion and Discovery Programs
The company expanded its pipeline to include discovery programs targeting new viral diseases such as RSV and measles, aiming to create best-in-class medicines beyond COVID-19.
Strong Financial Position and Cost Management
The company reported $11.3 million in net product revenue for Q1 2025 and a reduction in operating expenses by 15% quarter-over-quarter, with a strong cash position of $48 million and potential access to $30 million in non-dilutive funding.
Inclusion in Clinical Guidelines
PEMGARDA has been included in the NCCN Guidelines for B-cell lymphomas, indicating recognition from medical guidelines for its usage.
IVVD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IVVD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 15, 2025 | $0.84 | $0.70 | -16.67% |
Mar 20, 2025 | $0.72 | $0.74 | +2.78% |
Nov 14, 2024 | $0.89 | $0.79 | -11.24% |
Aug 14, 2024 | $1.06 | $0.98 | -7.55% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Invivyd (IVVD) report earnings?
Invivyd (IVVD) is schdueled to report earning on Aug 19, 2025, TBA Not Confirmed.
What is Invivyd (IVVD) earnings time?
Invivyd (IVVD) earnings time is at Aug 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IVVD EPS forecast?
IVVD EPS forecast for the fiscal quarter 2025 (Q2) is -0.02.